Serine protease inhibitor Kazal type 1 mutations and pancreatitis

被引:14
|
作者
Schneider, A [1 ]
机构
[1] Univ Heidelberg Hosp, Dept Med Gastroenterol Hepatol & Infect Dis 2, D-68135 Mannheim, Germany
关键词
D O I
10.1016/j.cll.2004.12.005
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Serine protease inhibitor Kazal type 1 is thought to play in important role in protecting the pancreas against excessive trypsinogen activation. Recent genetic studies have shown that mutations in the SPINK1 gene are associated with the development of acute and chronic pancreatitis. These findings further support the concept of intracellular trypsin activation as an initiating, and perhaps essential step in the development of acute and chronic pancreatitis This article focuses on the role of SPINK1 within the context of trypsin biology and trypsinogen gene mutations in hereditary pancreatitis and highlights the insights into the development of acute and chronic pancreatitis gained from recent investigations of the SPINK1 gene. This article summarizes the current knowledge of the phenotypic expression of pancreatitis with SPINK1 mutations and reports the current limitations in understanding the role of SPINK1 mutations in chronic pancreatitis.
引用
收藏
页码:61 / +
页数:19
相关论文
共 50 条
  • [41] The serine protease inhibitor of Kazal-type 7 (SPINK7) is expressed in human skin
    Weber, Clemens
    Fischer, Jan
    Redelfs, Lisa
    Rademacher, Franziska
    Harder, Juergen
    Weidinger, Stephan
    Wu, Zhihong
    Meyer-Hoffert, Ulf
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 2017, 309 (09) : 767 - 771
  • [42] Enhanced trypsin activity in pancreatic acinar cells deficient for serine protease inhibitor Kazal type 3
    Ohmuraya, Masaki
    Hirota, Masahiko
    Araki, Kimi
    Baba, Hideo
    Yamamura, Ken-ichi
    PANCREAS, 2006, 33 (01) : 104 - 106
  • [43] Serine protease inhibitor, Kazal type 1, promotes proliferation of pancreatic cancer cells through the epidermal growth factor receptor
    Ozaki, Nobuyuki
    Ohmuraya, Masaki
    Ida, Satoshi
    Sakamoto, Yasuo
    Tanaka, Hiroshi
    Takamori, Hiroshi
    Beppu, Toru
    Yamamura, Ken-ichi
    Baba, Hideo
    CANCER RESEARCH, 2009, 69
  • [44] Serine Protease Inhibitor Kazal Type 1 Promotes Proliferation of Pancreatic Cancer Cells through the Epidermal Growth Factor Receptor
    Ozaki, Nobuyuki
    Ohmuraya, Masaki
    Hirota, Masahiko
    Ida, Satoshi
    Wang, Jun
    Takamori, Hiroshi
    Higashiyama, Shigeki
    Baba, Hideo
    Yamamura, Ken-ichi
    MOLECULAR CANCER RESEARCH, 2009, 7 (09) : 1572 - 1581
  • [45] Regulation of serine protease inhibitor Kazal type-5 (SPINK5) gene expression in the keratinocytes
    Ngoc Anh Le
    Katsuyama, Midori
    Demura, Masashi
    Tanii, Hideji
    Katsuyama, Hironobu
    Saijoh, Kiyofumi
    ENVIRONMENTAL HEALTH AND PREVENTIVE MEDICINE, 2014, 19 (04) : 307 - 313
  • [46] A Kazal-type serine protease inhibitor mediates innate immunity in wild silkworm Actias selene Hubner
    Wang, Na
    Xie, Fengjiao
    Liu, Ya
    Jiang, Xiaoli
    Wei, Guoqing
    Zhu, Baojian
    Wang, Lei
    Qian, Cen
    JOURNAL OF BIOSCIENCES, 2022, 47 (02)
  • [47] Phenotypic Variability of the Homozygous IVS3+2T>C Mutation in the Serine Protease Inhibitor Kazal Type 1 (SPINK1) Gene in Patients with Chronic Pancreatitis
    Ota, Yuji
    Masamune, Atsushi
    Inui, Kazuo
    Kume, Kiyoshi
    Shimosegawa, Tooru
    Kikuyama, Masataka
    TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2010, 221 (03): : 197 - 201
  • [48] Autophagic cell death of pancreatic acinar cells in serine protease inhibitor Kazal Type 3 deficient mice
    Ohmuraya, Masaki
    Hirota, Masahiko
    Baba, Hideo
    Yamamura, Ken-Ichi
    GASTROENTEROLOGY, 2006, 130 (04) : A709 - A709
  • [49] Inhibition of human kallikreins 5 and 7 by the serine protease inhibitor lympho-epithelial Kazal-type inhibitor (LEKTI)
    Schechter, NM
    Choi, EJ
    Wang, ZM
    Hanakawa, Y
    Stanley, JR
    Kang, YA
    Clayman, GL
    Jayakumar, A
    BIOLOGICAL CHEMISTRY, 2005, 386 (11) : 1173 - 1184
  • [50] Serine protease inhibitor Kazal type 1 promotes epithelial-mesenchymal transition through EGFR signaling pathway in prostate cancer
    Wang, Chunni
    Wang, Lin
    Su, Bo
    Lu, Ning
    Song, Jingjing
    Yang, Xiaoqing
    Fu, Weiwei
    Tan, Weiwei
    Han, Bo
    PROSTATE, 2014, 74 (07): : 689 - 701